CDT

CDT Equity (formerly Conduit Pharmaceuticals) is a pre-clinical, pre-revenue biotech, and the numbers leave no room for interpretation. It has never booked revenue (FY2022–FY2025 all blank) and the 10-K is explicit: management does 'not expect to generate any significant revenues, if any, until we successfully complete adequate development of our first clinical asset,' and its lead candidates AZD1656 and AZD5904 are 'still in development and have not been approved by the FDA or any other regulatory body.' Losses are widening, not narrowing — net loss went from -$17.8M in FY2024 to -$39.2M in FY2025, against an accumulated deficit of -$68.3M. This is a research shell burning cash toward a binary, years-away licensing exit.

The balance sheet is the disqualifier. Stockholders' equity is negative at -$7.17M (liabilities of $12.8M exceed total assets of $5.65M), giving a nonsensical liabilities/equity of -1.79x — a solvency red flag, not a value signal. Cash is just $1.51M against operating cash burn of -$15.6M per year; even with current liabilities of $12.8M against $4.38M of current assets, the company has roughly a month of runway before it must raise. For a firm with no revenue and negative book value, any raise is dilutive equity or costly debt on brutal terms. The absurd diluted EPS of -$1177.89 alongside a share count that fell 27% to 4.86M points to a recent reverse split — a hallmark of a sub-$1 stock fighting delisting, and a warning that further reverse splits and dilution are likely.